Table 2. Gut microbiome enterotypes modify the association between statin use and markers of glucose homeostasis.

Percentage in the first four columns corresponds to the percent median increase in each marker between statin users and non-users within each enterotype. P-values in these columns correspond to t-tests comparing covariate adjusted values between statin users and non-users. Values shown are raw p-values, and those that remained significant after correcting for type-1-error (Bonferroni P<0.05) are bolded. The last three columns in the table show the F- and P-values for the statin-by-enterotype interaction term from ANOVA (unadjusted) and ANCOVA (covariate adjusted) models predicting each of the specified markers of glucose homeostasis. Covariate adjusted models were adjusted for microbiome vendor, clinical lab vendor, sex, age, BMI, LDL cholesterol and plasma HMG. Second to last column corresponds to models adjusted for the same covariates as well as T2D status (yes/no, N=1385, T2D n=64), while the last column corresponds to models adjusted for the same covariates as well as metformin use. P-values<0.05 are bolded. Abbreviations: HOMA-IR: Homeostatic Model Assessment for Insulin Resistance; HbA1c: Glycated Hemoglobin A1c.

	Bac.1	Rum.	Bac.2	Prev.	Unadjusted model N=1512	Covariate adj. model N=1512	Covariate and diabetes adj. model N=1385	Covariate and Metformin adj. model N=1512
HOMA-IR	73%, P=7.2e-07	21% P=0.27	99% P=1.2e-04	29% P=0.33	F=4.5, P=0.0037	F=2.6, P=0.0495	F=2.6, P=0.049	F=2.5, P=0.0595
Insulin	63% P=5.6e-06	19% P=0.17	89% P=9.1e-04	22% P=0.25	F=3.0, P=0.032	F=1.4, P=0.23	F=1.5, P=0.22	F=1.4, P=0.24
Glucose	6.6% P=9.7e-04	4.5% P=0.51	9.3% P=8.1e-04	7.6% P=0.84	F=6.4, P=0.00025	F=4.4, P=0.0041	F=3.9, P=0.0092	F=3.9, P=0.0083
HbA1c	5.6% P=2.0e-03	1.9% P=0.16	7.3% P=1.2e-04	1.8% P=0.57	F=8.1, P=2.3E-05	F=6.3, P=0.00030	F=3.4, P=0.017	F=5.6, P=0.00086